Importance Smoking tobacco is a well-established risk factor for multiple sclerosis (MS), a
chronic inflammatory disorder of the central nervous system usually characterized by bouts …

Productivity costs can strongly impact cost-effectiveness outcomes. This study investigated
the impact in the context of expensive hospital drugs. This study aimed to:(1) investigate the …

Natalizumab (Tysabri®) is a humanized monoclonal antibody against the α4 chain of
integrins and was the first targeted therapy to be approved for the treatment of relapsing …

Introduction and objective Multiple sclerosis (MS) is a chronic inflammatory disease of the
central nervous system. MS is considered incurable; however, disease treatment has …

Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for
aggressive forms of multiple sclerosis (MS) that has been derived from haematological …

Disease-modifying therapies (DMTs) are a core component of multiple sclerosis (MS)
management. Given current constraints on health care expenditures, the relative cost …

Purpose This study evaluated the cost-effectiveness of first-line treatments of relapsing–
remitting multiple sclerosis (RRMS)(dimethyl fumarate [DMF] 240 mg PO BID, teriflunomide …

Objective To evaluate the long-term costs and quality of life (QoL) with and without disease-
modifying treatments (DMTs) of patients with multiple sclerosis (MS). Methods Data on …

Multiple sclerosis (MS) is a chronic, inflammatory and immune-mediated disease of the
central nervous system (CNS), commonly affecting young adults and potentially associated …

Objective. To provide a current and comprehensive understanding of the cost‐effectiveness
of DMTs for the treatment of MS by quantitatively evaluating the quality of recent cost …